Redeye: Saniona - Hot (as summer!) in anticipated news flow

The main take away from this update should be that Saniona’s next 12 months will be intense, with several potential catalysts for the stock. We have also updated estimates in pipeline as well as financials for the current year.

Read more in the research update by Anders Hedlund:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Om oss

Saniona är ett forsknings- och utvecklingsbolag som bedriver läkemedelsutveckling av preparat som ska användas till sjukdomar i centrala nervsystemet, autoimmuna sjukdomar och behandling av smärta.